- Home
- IMUX
IMUX
Immunic Inc.
as 07-18-2025 2:35pm EST
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 67.8M | IPO Year: | N/A |
| Target Price: | $11.60 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.56 - $2.11 | Next Earning Date: | 08-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immunic Inc. (IMUX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tardio Jason | IMUX | President and COO | Jun 5 '25 | Buy | $0.79 | 25,024 | $19,768.96 | 12,512 | |
| Vitt Daniel | IMUX | CEO and Director | Jun 4 '25 | Buy | $0.77 | 30,000 | $23,100.00 | 29,000 | |
| Neermann Joerg | IMUX | Director | Jun 4 '25 | Buy | $0.77 | 100,000 | $76,700.00 | 170,000 | |
| Whaley Glenn | IMUX | Chief Financial Officer | Jun 3 '25 | Buy | $0.71 | 45,000 | $32,076.00 | 95,510 | |
| Rudick Richard Alan | IMUX | Director | Jun 3 '25 | Buy | $0.70 | 143,075 | $100,023.73 | 230,375 |
Latest Immunic Inc. News
IMUX Breaking Stock News: Dive into IMUX Ticker-Specific Updates for Smart Investing
PR Newswire
25 days ago
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 06/06/2025
MT Newswires
a month ago
Immunic Completes Enrollment in 2 Phase 3 Studies in Relapsing Multiple Sclerosis
PR Newswire
a month ago
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
PR Newswire
2 months ago
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
PR Newswire
2 months ago
Immunic to Participate in Investor, Scientific and Industry Conferences in June
MT Newswires
2 months ago
Immunic Tumbles After Pricing $65 Million Offering of Warrants
PR Newswire
2 months ago
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
Compare IMUX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMUX Immunic Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.